The neuronopathic forms of the human inherited metabolic disorder, Gaucher disease (GD), are characterized by severe neuronal loss, astrogliosis and microglial proliferation, but the cellular and molecular pathways causing these changes are not known. Recently, a mouse model of neuronopathic GD was generated in which glucocerebrosidase deficiency is limited to neural and glial progenitor cells. We now show significant changes in the levels and in the distribution of cathepsins in the brain of this mouse model. Cathepsin mRNA expression was significantly elevated by up to ∼10-fold, with the time-course of the increase correlating with the progression of disease severity. Cathepsin activity and protein levels were also elevated. Significant changes in cathepsin D distribution in the brain were detected, with cathepsin D elevated in areas where neuronal loss, astrogliosis and microgliosis were observed, such as in layer V of the cerebral cortex, the lateral globus pallidus and in various nuclei in the thalamus, brain regions known to be affected in the disease. Cathepsin D elevation was greatest in microglia and also noticeable in astrocytes. The distribution of cathepsin D was altered in neurons in a manner consistent with its release from the lysosome to the cytosol. Remarkably, ibubrofen treatment significantly reduced cathepsin D mRNA levels in the cortex of Gaucher mice. Finally, cathepsin levels were also altered in mouse models of a number of other sphingolipidoses. Our findings suggest the involvement of cathepsins in the neuropathology of neuronal forms of GD and of other lysosomal storage diseases, and are consistent with a crucial role for reactive microglia in neuronal degeneration in these diseases.
INTRODUCTION
Lysosomal storage disorders (LSDs) are a group of inherited human metabolic disorders caused by the impaired catalytic activity of lysosomal enzymes. As a consequence, the substrate of the defective enzyme accumulates in lysosomes causing disease pathology. Over 40 LSDs are known (1, 2) and each disease differs in its clinical course and severity, depending on the type of accumulating substrate, its levels and the tissues or cells in which it accumulates. The sphingolipidoses are a subgroup of LSDs characterized by the intralysosomal accumulation of sphingolipids (3) . Gaucher disease (GD), the most common LSD, is caused by the defective activity of glucosylceramidase (GlcCerase), the lysosomal hydrolase that degrades glucosylceramide (GlcCer). The chronic non-neuronopathic form of GD is the most common (.90% of patients) (4) . The acute neuronopathic forms of GD (nGD) are characterized by severe neuronal loss and by astrogliosis (5); however, little is known about how intracellular accumulation of GlcCer leads to neuronal cell loss and tissue dysfunction.
In the current study, we show alterations in the expression and distribution of cathepsins in the brain of a mouse model of acute nGD, as well as in mouse models of other LSDs. Cathepsins are ubiquitous lysosomal proteases that play important roles in normal protein recycling and in the proper functioning of the cell (6) . The cathepsin family comprises aspartic (cathepsins D and E) and cysteine proteases (cathep-sins B, C, F, H, K, L, O, S, V, W and Z). In addition to their roles in lysosomal protein turnover, cathepsins also activate apoptotic and necrotic pathways upon their release into the cytosol after lysosomal membrane permeabilization (7) . In the central nervous system, cathepsins S (CTSS), B (CTSB) and D (CTSD) are released from activated microglia, which can cause neuronal death through the degradation of extracellular matrix proteins (8 -10) . Disturbance of the normal balance and extra-lysosomal localization of cathepsins has been observed in several neurodegenerative conditions such as Alzheimer's disease, stroke, age-related neurodegeneration and amyotrophic lateral sclerosis (11) (12) (13) (14) (15) (16) . Elevated levels of cathepsins were also found in some LSDs. For instance, CTSD was elevated in neurons and microglia in NiemannPick C disease, and mRNA expression of CTSB, CTSS and cathepsin C was elevated in Tay -Sachs and Sandhoff disease (17) (18) (19) (20) (21) . Gene expression studies demonstrated elevated cathepsins B, K and S in the spleen of type 1 GD patients and upregulation of CTSB in the cortex of one nGD patient (22, 23) . However, the role of cathepsins in nGD and in the pathological progression of other sphingolipidoses has not been systematically studied.
RESULTS
Upregulation of cathepsin mRNA levels in nGD mice mRNA levels of eight cysteine cathepsins (cathepsins B, F, H, K, L, O, S, Z) and the aspartic cathepsin, CTSD, were systematically examined by quantitative RT -PCR (qPCR) in a mouse model of nGD (the Gba flox/flox ;Nestin-Cre mouse, hereafter referred to as the Nestin-flox/flox mouse). In these mice, GlcCerase deficiency is restricted to neural and glial progenitor cells. These mice exhibit rapid motor dysfunction associated with severe neurodegeneration and neuronal loss, and develop paralysis by 21 days of age (24) .
Cathepsin levels were examined in the cerebral cortex obtained from mice at three different stages of disease development, the pre-symptomatic stage (9 days of age), the initial time at which symptoms are observed (14 days) and the most severe stage of the disease (21 days). No differences were observed in cathepsin mRNA levels in the cortex of 9-day-old Nestin-flox/flox compared with control (Nestinflox/wt) mice (Fig. 1) . By 14 days of age, levels of cathepsins D, Z and S were significantly elevated, by up to 5-fold, and cathepsin B, H and L expression were elevated by 2 -3-fold ( Fig. 1) . By 21 days of age, much larger changes were observed in the expression of most cathepsins, reaching levels 10-fold greater than controls for cathepsins D, Z, S, B, and 2 -3-fold greater for cathepsins H, L and O. Cathepsins F and K were unaltered at all stages (Fig. 1) . The lack of change in mRNA expression of six unrelated lysosomal proteins, lysosomal-associated membrane protein 1 (Lamp1) and lysosomal integral membrane protein (Limp-2) (Fig. 1) , and b-galactosidase, sphingomyelinase, hyaluronidase 1 and the membrane protein ATP-binding cassette subfamily A (not shown), demonstrates that the mRNA expression of only a subset of lysosomal proteins is altered in nGD cortex (Fig. 1) . However, western blotting revealed some elevation of Lamp1 protein levels, consistent with an earlier study using human skin fibroblasts (25) .Thus, these results indicate a specific increase in cathepsin mRNA expression in the brain of nGD mice, which correlates with the progression of disease severity.
Increased cathepsin D and B protein levels
We next analyzed whether the changes in mRNA expression are accompanied by corresponding changes in cathepsin Figure 1 . Age-related increase of cathepsin mRNA levels in the cerebral cortex of nGD mice. Cathepsin mRNA levels were measured by qPCR on total mRNA extracted from the cortex of Nestin-flox/flox mice and compared with Nestin-flox/wt mice. Results are expressed as a ratio, and are means + SEM (n ¼ 3 for 9-and 21-day-old mice, and n ¼ 2 -3 for 14-day-old mice).
* P , 0.05; * * P , 0.01; * * * P , 0.001. CT values were normalized to levels of HPRT or TBP.
protein levels, using homogenates from the cortex of 21-day-old Nestin-flox/flox mice. Cathepsins D and B are synthesized as a pre-proenzyme, transported through the Golgi apparatus as a proenzyme, and reside in the lysosome as an active intermediate single chain form and a mature form consisting of two chains (26) . A significant increase in levels of the CTSD intermediate (47 kDa) and mature forms (34 and 14 kDa) ( Fig. 2A) , and in the CTSB mature form (25 kDa) ( Fig. 2B ), was observed in nGD mice. This is reflected in an 3-fold increase in CTSD activity in cortical homogenates from Nestin-flox/flox mice (Fig. 2C) .
Distribution of CTSD in neuronal tissues
Immunohistochemical analysis was performed to determine in which brain regions and in which cell types CTSD was elevated in nGD mice. CTSD immunoreactivity was significantly elevated in the brain of 14-16-day-old Nestin-flox/flox mice, and specifically in layer V of the cerebral cortex, the lateral globus pallidus and various nuclei in the thalamus (Fig. 3E) . Double labeling using an anti-NeuN antibody (to label neurons), an anti-GFAP antibody (to label astrocytes) and an anti-mac-2 antibody (to label microglia) revealed that CTSD was elevated in areas where neuronal loss, astrogliosis and microgliosis were observed (Fig. 3H , G and F), although at this stage, neuronal loss was not seen in the thalamus. Moreover, CTSD levels were mainly elevated in microglia and could be detected occasionally in astrocytes, but not in neurons (Fig. 4) . Interestingly, however, the distribution of CTSD was altered in neurons. In the brain of 14-day-old control mice, CTSD was expressed in large neurons and co-localized within vesicular structures with 40 puncta per neuron ( Fig. 5C and F) , presumably lysosomes. In neurons from Nestin-flox/flox mice, CTSD labeling was much more diffuse with 15 puncta per neuron ( Fig. 5D and F) , implying that CTSD is secreted from lysosomes into the cytosol. The changes in the intracellular distribution of CTSD were observed at the stage when symptoms first appear (14 days) (Fig. 5C , D and F) but not in pre-symptomatic (10 days) mice, where 40 puncta per neuron were detected in both Nestin-flox/flox and control mice (Fig. 5A , B and E).
Cathepsin levels in other sphingolipidoses
We also examined whether CTSD and CTSB levels are elevated in the brain of other sphingolipidoses mouse models. Western blot analyses revealed a marked elevation of both CTSD and CTSB in the cortex of Sandhoff disease, GM1 gangliosidosis and Niemann -Pick A mouse models (Fig. 6 ). All three diseases are characterized by neurological impairment.
Effect of non-steroidal anti-inflammatory drugs on cathepsin mRNA levels in nGD mice
Since CTSD levels were mainly elevated in microglia in Nestin-flox/flox mice, we examined the relationship between CTSD elevation and neuroinflammation by treating nGD mice with a non-steroidal anti-inflammatory drug, ibuprofen. Mice were injected prior to symptom onset (at 10 days of age), and subsequently for 6 days. Remarkably, ibuprofen treatment significantly decreased the extent of elevation of CTSD and CTSZ mRNA levels ( Fig. 7A and B) , but had no effect on mRNA levels of CTSB and CTSS ( Fig. 7C and D) .
DISCUSSION
The acute form of nGD is characterized by the rapid progression and appearance of extensive brain pathology, which invariably leads to the death of the patient. Among the pathological findings are neurodegeneration, astrogliosis and microglial proliferation (5), but little progress has been made in understanding the biochemical pathways that lead to these pathological events. We now demonstrate a connection between increased levels of cathepsins B, D, H, L, S and Z in the cerebral cortex of a mouse model of nGD and disease progression, inasmuch as a strong correlation was observed between the time of changes in cathepsin levels and the time of appearance of disease symptoms. Moreover, the elevation of CTSD was detected in layer V of the cortex, in the lateral globus pallidus and in various nuclei in the thalamus, the same regions which display neuronal loss, astrogliosis and microgliosis in the disease (5, 24) , suggesting that the changes in cathepsin expression are directly related to disease pathology.
In addition to their main function in lysosomal protein recycling, altered activity and/or distribution of cathepsins have been shown to lead to neuronal death in various neurodegenerative disorders and pathological conditions. Cathepsin Z (also known as cathepsin X or P) (27) , which is ubiquitously expressed in various tissues including the brain (28) and exhibits high expression in monocytes and macrophages (29) , is up-regulated in the brain, mainly in glial cells, during aging and in amyotrophic lateral sclerosis (30) , consistent with it playing a role in inflammation and neurodegeneration. Elevated expression of cathepsin H was shown in multiple sclerosis, amyotrophic lateral sclerosis and Huntington's disease (31 -33) , and cathepsin S is highly expressed in phagocytic cells and plays an important role in the proteolytic events that lead to antigen presentation (34) . Several lines of evidence suggest that activated microglia secrete cathepsins to induce neuronal death by degradation of extracellular matrix proteins. Among these are cathepsin B, D, L and S (8 -10,33,35,36) . In addition, cathepsins B, D and L have been implicated in cell death by activating apoptotic effectors such as mitochondria and/or caspases upon their release to the cytosol (7). In Nestinflox/flox mice, CTSD elevation was highest in microglia and was also noticeable in astrocytes. Moreover, in neurons, there was a significant change in CTSD distribution, consistent with the likelihood that CTSD is secreted from lysosomes, perhaps implying changes in the neuronal endosomal/ lysosomal system.
It should be emphasized that in Nestin-flox/flox nGD mice, microglial are unaffected and express normal GlcCerase levels (24) . Nevertheless, microglia show the greatest changes in CTSD levels, indicating that the changes in microglia CTSD levels are not the result of GlcCer accumulation in the microglia themselves, but rather a consequence of GlcCer accumulation in other cell types such as neurons and/or astrocytes. Interestingly, incubation of cultured hippocampal neurons, cultured astrocytes or cultured microglial BV-2 cells with conduritol B-epoxide, an active site-directed inhibitor of GlcCerase, did not result in changes of CTSD levels in any of the cultured cells (data not shown). This supports the notion that CTSD elevation in microglia is not a direct result of intracellular GlcCer accumulation per se, but rather the result of the interplay between various cell types in vivo. Our results strongly suggest that reactive microglia play a crucial role in neuron degeneration in nGD, and that reducing inflammation, with treatments such as non-steroidal anti-inflammatory drugs (i.e. ibuprofen), might alleviate the symptoms caused by inflammation. Interestingly, levels of only a subset of cathepsins changed after ibuprofen treatment, suggesting that different molecular mechanisms are involved in the changes in both subsets of cathepsins.
Finally, we found that elevated levels of CTSD and CTSB also occur in other sphingolipidoses, all of which are characterized by progressive neurodegeneration and microglia activation, ultimately leading to death (21, 37) . The increase in CTSB in Sandhoff disease is consistent with a previous study (19) .
In conclusion, we have shown that cathepsin levels are highly elevated in the cerebral cortex of a mouse model of nGD, that these changes correlate with the rate of disease progression and that treatment with ibuprofen significantly reduces expression levels of a subset of cathepsins. Moreover, elevation of CTSD was detected in the same brain regions that are affected in the disease, with CTSD elevation greatest in microglia, suggesting that reactive microglia may play a crucial role in neuron degeneration. Since no therapies are currently available for nGD, determining the role of cathepsins along with the role of activated microglia may potentially offer new therapeutic approaches for disease management.
MATERIALS AND METHODS

Animals
Nestin-flox/flox mice were used as a model of nGD (24) . Gba flox/flox females were crossed with Gba flox/+ ;Nestin-Cre males to generate Gba flox/flox ;Nestin-Cre mice (the Nestinflox/flox Gaucher mouse), and Gba flox/+ ;Nestin-Cre mice (referred to as Nestin-flox/wt), which served as healthy controls. Genotyping was performed by PCR using genomic DNA extracted from mouse tails or embryonic brains (38) . The colony was maintained in the Experimental Animal Center of the Weizmann Institute of Science.
Mice deficient in the b-subunit of b-hexosaminidase A and B (Hexb) were used as a model of Sandhoff disease (39) .
Brains from a mouse model of the GM1 gangliosidosis (40) , defective in lysosomal b-galactosidase activity, were provided by Dr Frances Platt (Oxford University). Mice defective in the activity of acid sphingomyelinase were used as Niemann -Pick disease type A model (41) .
RNA extraction and qPCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to manufacturer's instructions, which included a DNAse step and addition of b-mercaptoethanol. cDNA synthesis was performed using the Reverse-iT First-strand Synthesis Kit (Thermo Scientific) using random decamers. cDNA products were stored at 2208C. qPCR was performed using the SYBR Green PCR Master Mix (Finnzyme) and an ABI Prism 7000 Sequence Detection System (Applied Biosystems) with cDNA (equivalent to 5 ng of total RNA). The primer concentration was 13 nM in a reaction volume of Figure 7 . Cathepsin mRNA levels after ibuprofen injection. Cathepsin mRNA levels were measured by qPCR on total mRNA extracted from the cortex of Nestin-flox/flox mice and compared with Nestin-flox/wt mice, after i.p. injection with ibuprofen (IBU) (50 mg/kg/day) or PBS. Results are expressed as a ratio and are means + SEM (n ¼ 5).
* P , 0.01; * * P , 0.001. CT values were normalized to levels of HPRT. 20 ml. Each reaction was performed in triplicate. The thermal cycling parameters were as follows: step 1, 958C for 10 min; step 2, 958C for 15 s; step 3, 608C for 30 s, 688C for 30 s.
Step 2 was repeated for 40 cycles and was followed by a dissociation step. The relative amounts of mRNA were calculated from the cycle threshold (CT) values using HPRT or TBP for normalization. Primer sequences are listed in Table 1 . P-values were calculated using a one-tailed two-independent samples Student's t-test. A P-value ,0.05 was considered statistically significant.
Western blotting
Brain tissue was lysed in approximately six volumes of Triton X-100 lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM DTT, 0.5 mM EDTA) supplemented with protease and phosphatase inhibitor cocktails (1:100, Sigma). Following homogenization, samples were centrifuged at 14 000g av for 20 min at 48C, and the supernatants were collected. Protein was quantified using the BCA protein assay reagent (Pierce Chemical Co.). An amount of 50 mg of protein in the sample buffer was electrophoresed on a 12% SDS -polyacrylamide gel and transferred to a nitrocellulose membrane. Blots were incubated with the following primary antibodies: goat anti-CTSD or rabbit anti-CTSB (Santa Cruz, 1:500 dilution) and mouse anti-tubulin (Sigma) (1:500 000 dilution), and then incubated with a horseradish peroxidaseconjugated secondary antibody (Jackson ImmunoResearch). Bound antibodies were detected using the SuperSignal West Pico chemiluminescent substrate (Thermo Scientific).
CTSD activity
CTSD activity was assayed using a fluorometric assay kit from BioVision Research Products according to the manufacturer's protocol, using the CTSD substrate GKPILFFRLK(Dnp)-D-R-NH2.
Immunohistochemistry
Mice were anesthetized with 2.5% isoflurane in oxygen, killed and the brains rapidly excised. Brains were fixed in 2.5% paraformaldehyde for 2 days. Paraffin sections (7 mm thick) were prepared on Superfrost+ slides and stored at 48C until use. The paraffin sections were deparaffinized and antigen retrieval was performed using 10 mM citric acid (pH 6.0) for 10 min. To reduce the non-specific signal, sections were blocked using 20% horse serum (Vector, Burlingame, CA, USA) and 0.2% Triton X-100. Sections were incubated with either a mixture of CTSD (goat, polyclonal 1:200, Santa Cruz) and NeuN (mouse, monoclonal, 1:50, Chemicon, Temecula, CA, USA) antibodies, or a mixture of CTSD with rat anti-mac-2 (1:250, Cedarlane, Ontario, Canada) or rabbit anti-GFAP (1:200, Dako, Denmark). Antibody mixtures were diluted in 2% horse serum containing 0.5% Triton X-100 for NeuN staining and 0.2% Triton X-100 for the others. Sections were incubated with the first antibodies overnight at room temperature. For CTSD detection, sections were incubated with biotinylated donkey anti-goat secondary antibody Floating sections of 16-day-old brains (20 mm) were cut on an SM 2000 R microtome (Leica, Germany) and stored in phosphate-buffered saline (PBS) with 0.05% sodium azide at 48C until use. After blocking with 20% horse serum containing 0.2% Triton X-100, floating sections were incubated overnight with primary and secondary antibodies as above. All antibodies were diluted in 0.2% horse serum and 0.5%/0.2% Triton X-100 in PBS, and after each application, triple washings with PBS were performed. All incubations were performed at room temperature.
Drug treatment
Ibuprofen (Sigma, 50 mg/kg/day) was administered by i.p. injection daily for 6 days to 10-16-day-old Nestin-flox/flox and Nestin-flox/wt mice. Control mice were injected i.p. with PBS. 
